Perfluorohexyloctane Ophthalmic Solution Adverse Events from FAERS, 2023-2024

Zhengtai Sun's pharmacovigilance study analyzes 92 adverse event reports for perfluorohexyloctane ophthalmic solution, a treatment for dry eye disease. The analysis uses FDA Adverse Event Reporting System (FAERS) data from Q4 2023 through Q4 2024 and employs four disproportionality methods to identify safety signals. The median time-to-onset for reported adverse events was 2 days.

Use Cases

• Identify potential safety signals for a novel dry eye disease treatment based on disproportionality analysis methods.
• Analyze the nature and timing of reported adverse events, such as product delivery issues and patient dissatisfaction.
• Support clinical risk management strategies based on real-world adverse event data from a regulatory database.

Strengths

• Analysis is based on 92 adverse event reports from the authoritative FAERS database.
• Employs four established disproportionality analysis methods (ROR, PRR, BCPNN, MGPS) for signal detection.
• Provides a specific median time-to-onset of 2 days for reported events.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect reporting bias inherent to voluntary adverse event reporting systems.

Provenance

Source

FDA Adverse Event Reporting System (FAERS)

Collection Method

Retrospective pharmacovigilance study using disproportionality analysis.

Time Range

Fourth quarter of 2023 through fourth quarter of 2024

Freshness

Last updated 2026-05-28 04:48:12; freshness should be verified.